Research programme: inflammation and immunological therapeutics - MiNA Therapeutics
Latest Information Update: 16 Aug 2023
Price :
$50 *
At a glance
- Originator MiNA Therapeutics
- Class Oligonucleotides; RNA; Vascular disorder therapies
- Mechanism of Action Complement C1 inhibitor protein expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Autoimmune disorders; Hereditary angioedema
Most Recent Events
- 01 Aug 2023 Research programme: inflammation and immunological therapeutics - MiNA Therapeutics is available for licensing as of 01 Aug 2023. https://minatx.com/ (MiNA Therapeutics website; July 2023)
- 21 Jul 2023 Early research in Autoimmune disorders in United Kingdom (Parenteral) (MiNA Therapeutics pipeline; July 2023)
- 21 Jul 2023 Early research in Hereditary angioedema in United Kingdom (Parenteral) (MiNA Therapeutics pipeline; July 2023)